Cargando…

Engineering of Amphiphilic Erlotinib Analogue as Novel Nanomedicine for Non-Small Cell Lung Cancer Therapy

PURPOSE: Molecular targeted therapy is one of the most pivotal strategies in the treatment of non-small cell lung cancer, yet its curative effect is severely compromised by the poor aqueous solubility, low bioavailability and inadequate tumor accumulation of targeted agents. To enhance the efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cong, Mei, Pang, Houjun, Xie, Guangxing, Li, Feifei, Li, Chunxiao, Sun, Hao, Yang, Shaoyou, Zhao, Weidong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638928/ https://www.ncbi.nlm.nih.gov/pubmed/37954452 http://dx.doi.org/10.2147/IJN.S432464

Ejemplares similares

Amphiphilic Dendritic Nanomicelle-Mediated Delivery of Gemcitabine for Enhancing the Specificity and Effectiveness
por: Zhao, Weidong, et al.
Publicado: (2022)

In vitro evaluation of anticancer nanomedicines based on doxorubicin and amphiphilic Y-shaped copolymers
por: Li, Di, et al.
Publicado: (2012)

Surface Engineering of Nanomaterials with Polymers, Biomolecules, and Small Ligands for Nanomedicine
por: Díez-Pascual, Ana M.
Publicado: (2022)

Peptide Amphiphiles in Corneal Tissue Engineering
por: Miotto, Martina, et al.
Publicado: (2015)

Identifying erlotinib-sensitive non-small cell lung carcinoma tumors in mice using [(11)C]erlotinib PET
por: Abourbeh, Galith, et al.
Publicado: (2015)

Engineering of small-molecule lipidic prodrugs as novel nanomedicines for enhanced drug delivery
por: Huang, Lingling, et al.
Publicado: (2022)

Recent trends in nanomedicine and tissue engineering
por: Thomas, Jince, et al.
Publicado: (2018)

Engineered Nanomaterials: The Challenges and Opportunities for Nanomedicines
por: Albalawi, Fahad, et al.
Publicado: (2021)

Engineering Prodrug Nanomedicine for Cancer Immunotherapy
por: Yang, Bin, et al.
Publicado: (2020)

Meta-analysis of efficacy and adverse events of erlotinib-based targeted therapies for advanced/metastatic non-small cell lung cancer
por: Li, Fei, et al.
Publicado: (2017)

Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials
por: Li, Ruijian, et al.
Publicado: (2023)

Repurposing sertraline sensitizes non–small cell lung cancer cells to erlotinib by inducing autophagy
por: Jiang, Xingwu, et al.
Publicado: (2018)

Genetic Association of Drug Response to Erlotinib in Chinese Advanced Non-small Cell Lung Cancer Patients
por: Wang, Cong, et al.
Publicado: (2018)

Role of erlotinib in the targeted treatment of non-small-cell lung cancer in Chinese patients
por: Li, Wei, et al.
Publicado: (2014)

Review of erlotinib in the treatment of advanced non-small cell lung cancer
por: Ganjoo, Kristen N, et al.
Publicado: (2007)

Micelle Structure Details and Stabilities of Cyclic Block Copolymer Amphiphile and Its Linear Analogues
por: Ree, Brian J., et al.
Publicado: (2019)

Nano-engineering nanomedicines with customized functions for tumor treatment applications
por: Wang, Yuxin, et al.
Publicado: (2023)

Ultra-small polydopamine nanomedicine-enabled antioxidation against senescence
por: Han, Jiamei, et al.
Publicado: (2023)

Engineering tumor-specific gene nanomedicine to recruit and activate T cells for enhanced immunotherapy
por: Wang, Yue, et al.
Publicado: (2023)

Ultra-Small Lysozyme-Protected Gold Nanoclusters as Nanomedicines Inducing Osteogenic Differentiation
por: Li, Kuo, et al.
Publicado: (2020)

Mer receptor tyrosine kinase is frequently overexpressed in human non-small cell lung cancer, confirming resistance to erlotinib
por: Xie, Shengzhi, et al.
Publicado: (2015)

Successful erlotinib rechallenge after both gefitinib- and erlotinib-induced interstitial lung diseases
por: Arakawa, Nobuhito, et al.
Publicado: (2013)

Combination Erlotinib-Cisplatin and Atg3-Mediated Autophagy in Erlotinib Resistant Lung Cancer
por: Lee, Jasmine G., et al.
Publicado: (2012)

YAP promotes erlotinib resistance in human non-small cell lung cancer cells
por: Hsu, Ping-Chih, et al.
Publicado: (2016)

Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients
por: Xiong, Liwen, et al.
Publicado: (2019)

Editorial: Emerging Advances in Bio-Nano Engineered Approaches Toward Intelligent Nanomedicine
por: Wang, Junqing, et al.
Publicado: (2021)

NCAPG2 Maintains Cancer Stemness and Promotes Erlotinib Resistance in Lung Adenocarcinoma
por: Jiang, Shiyao, et al.
Publicado: (2022)

Advanced targeted nanomedicine: a communication engineering solution
por: Chude-Okonkwo, Uche, et al.
Publicado: (2019)

Endocytosis of Nanomedicines: The Case of Glycopeptide Engineered PLGA Nanoparticles
por: Vilella, Antonietta, et al.
Publicado: (2015)

Engineering Tumor-Targeting Nanoparticles as Vehicles for Precision Nanomedicine
por: Gonda, Amber, et al.
Publicado: (2019)

Strategies for engineering advanced nanomedicines for gas therapy of cancer
por: Wang, Yingshuai, et al.
Publicado: (2020)

Heterojunction Nanomedicine
por: Pan, Chao, et al.
Publicado: (2022)

Inhibition of mitochondrial glutaminase activity reverses acquired erlotinib resistance in non-small cell lung cancer
por: Xie, Caifeng, et al.
Publicado: (2015)

Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer
por: Rudin, C.M., et al.
Publicado: (2023)

Erlotinib ‘dosing-to-rash’: a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer
por: Mita, A C, et al.
Publicado: (2011)

Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis
por: Zhang, Shu, et al.
Publicado: (2016)

RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship
por: Nakagawa, Kazuhiko, et al.
Publicado: (2022)

Comparing Efficacy of Erlotinib and Bevacizumab Combination with Erlotinib Monotherapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis
por: Sakharkar, Prashant, et al.
Publicado: (2023)

Efficacy of erlotinib and celecoxib for patients with advanced non-small cell lung cancer: A retrospective study
por: Jin, Yi-Hua, et al.
Publicado: (2019)

Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study
por: Emery, Ivette F, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_up21fejjiptqa6sipljlpahib5